Swedish immuno-oncology company Immunicum AB (STO:IMMU) reported on Monday encouraging signs of a survival benefit in its Phase II MERECA trial evaluating its off-the-shelf cell-based cancer immunotherapy, ilixadencel, in combination with sunitinib in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma (mRCC).
In the study, 88 patients were randomly assigned to the ilixadencel combination group or sunitinib control group, and subsequently followed for survival. The co-primary endpoint of median OS was reached at 25.3 months in the sunitinib control group, while the median OS in the ilixadencel treatment group has now been reached at 35.6 months.
"The observed difference of 10 months in median OS for the ilixadencel combination group versus the control group is substantial and clinically meaningful," commented Peter Suenaert, M.D, PhD, Immunicum's chief medical officer. "Although the randomised, controlled study was not statistically powered for the OS endpoint, the data announced today suggests that ilixadencel has the potential to become a promising treatment option for these patients by improving survival outcomes when combined with standard-of-care cancer therapies."
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients